Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Anti-VEGF antibody therapy with bevacizumab provides significant clinical benefit in patients with recurrent glioblastoma multiforme (GBM). Unfortunately, progression on bevacizumab therapy is often associated with a diffuse disease recurrence pattern, which limits subsequent therapeutic options. Th...

Full description

Bibliographic Details
Main Authors: Deborah Huveldt, Laura J Lewis-Tuffin, Brett L Carlson, Mark A Schroeder, Fausto Rodriguez, Caterina Giannini, Evanthia Galanis, Jann N Sarkaria, Panos Z Anastasiadis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3572988?pdf=render

Internet

http://europepmc.org/articles/PMC3572988?pdf=render

Similar Items